These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 19770002)
61. Persistent therapeutic effect of a novel α5-GABA Gacsályi I; Móricz K; Gigler G; Megyeri K; Machado P; Antoni FA Eur J Pharmacol; 2018 Sep; 834():118-125. PubMed ID: 30012500 [TBL] [Abstract][Full Text] [Related]
62. Aldehyde oxidase and its contribution to the metabolism of a structurally novel, functionally selective GABAA alpha5-subtype inverse agonist. O'Connor D; Jones P; Chambers MS; Maxey R; Szekeres HJ; Szeto N; Scott-Stevens P; Macleod AM; Braun M; Cato B Xenobiotica; 2006 Apr; 36(4):315-30. PubMed ID: 16684711 [TBL] [Abstract][Full Text] [Related]
63. In vivo pharmacological characterization of AC-3933, a benzodiazepine receptor partial inverse agonist for the treatment of Alzheimer's disease. Hatayama Y; Hashimoto T; Kohayakawa H; Kiyoshi T; Nakamichi K; Kinoshita T; Yoshida N Neuroscience; 2014 Apr; 265():217-25. PubMed ID: 24513386 [TBL] [Abstract][Full Text] [Related]
64. NS11821, a partial subtype-selective GABAA agonist, elicits selective effects on the central nervous system in randomized controlled trial with healthy subjects. Zuiker RG; Chen X; Østerberg O; Mirza NR; Muglia P; de Kam M; Klaassen ES; van Gerven JM J Psychopharmacol; 2016 Mar; 30(3):253-62. PubMed ID: 26655084 [TBL] [Abstract][Full Text] [Related]
65. Blockade of alcohol's amnestic activity in humans by an alpha5 subtype benzodiazepine receptor inverse agonist. Nutt DJ; Besson M; Wilson SJ; Dawson GR; Lingford-Hughes AR Neuropharmacology; 2007 Dec; 53(7):810-20. PubMed ID: 17888460 [TBL] [Abstract][Full Text] [Related]
66. 6,7-Dihydro-2-benzothiophen-4(5H)-ones: a novel class of GABA-A alpha5 receptor inverse agonists. Chambers MS; Atack JR; Bromidge FA; Broughton HB; Cook S; Dawson GR; Hobbs SC; Maubach KA; Reeve AJ; Seabrook GR; Wafford K; MacLeod AM J Med Chem; 2002 Mar; 45(6):1176-9. PubMed ID: 11881985 [TBL] [Abstract][Full Text] [Related]
67. GABAA receptor subtype-selective modulators. II. α5-selective inverse agonists for cognition enhancement. Atack JR Curr Top Med Chem; 2011; 11(9):1203-14. PubMed ID: 21050171 [TBL] [Abstract][Full Text] [Related]
68. GABAA receptor subtypes: Therapeutic potential in Down syndrome, affective disorders, schizophrenia, and autism. Rudolph U; Möhler H Annu Rev Pharmacol Toxicol; 2014; 54():483-507. PubMed ID: 24160694 [TBL] [Abstract][Full Text] [Related]
69. Selective GABA(A) α5 positive allosteric modulators improve cognitive function in aged rats with memory impairment. Koh MT; Rosenzweig-Lipson S; Gallagher M Neuropharmacology; 2013 Jan; 64(1):145-52. PubMed ID: 22732440 [TBL] [Abstract][Full Text] [Related]
70. Specific targeting of the GABA-A receptor α5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice. Braudeau J; Delatour B; Duchon A; Pereira PL; Dauphinot L; de Chaumont F; Olivo-Marin JC; Dodd RH; Hérault Y; Potier MC J Psychopharmacol; 2011 Aug; 25(8):1030-42. PubMed ID: 21693554 [TBL] [Abstract][Full Text] [Related]
71. The physiological properties and therapeutic potential of alpha5-GABAA receptors. Martin LJ; Bonin RP; Orser BA Biochem Soc Trans; 2009 Dec; 37(Pt 6):1334-7. PubMed ID: 19909271 [TBL] [Abstract][Full Text] [Related]
72. An Emerging Circuit Pharmacology of GABA Engin E; Benham RS; Rudolph U Trends Pharmacol Sci; 2018 Aug; 39(8):710-732. PubMed ID: 29903580 [TBL] [Abstract][Full Text] [Related]
73. Memory deficits induced by inflammation are regulated by α5-subunit-containing GABAA receptors. Wang DS; Zurek AA; Lecker I; Yu J; Abramian AM; Avramescu S; Davies PA; Moss SJ; Lu WY; Orser BA Cell Rep; 2012 Sep; 2(3):488-96. PubMed ID: 22999935 [TBL] [Abstract][Full Text] [Related]
74. Effects of chronic stress on cognitive function - From neurobiology to intervention. Girotti M; Bulin SE; Carreno FR Neurobiol Stress; 2024 Nov; 33():100670. PubMed ID: 39295772 [TBL] [Abstract][Full Text] [Related]
75. Basmisanil, an α5-GABA Daher F; Villalobos NA; Hanley M; Atack JR; Popa MO; Fogaça MV Neurosci Lett; 2024 Jun; 833():137828. PubMed ID: 38772437 [TBL] [Abstract][Full Text] [Related]
76. Control of contextual memory through interneuronal α5-GABA Zhu M; Abdulzahir A; Perkins MG; Chu CC; Krause BM; Casey C; Lennertz R; Ruhl D; Hentschke H; Nagarajan R; Chapman ER; Rudolph U; Fanselow MS; Pearce RA PNAS Nexus; 2023 Apr; 2(4):pgad065. PubMed ID: 37056471 [TBL] [Abstract][Full Text] [Related]
77. The fate of interneurons, GABA Ali AB; Islam A; Constanti A Brain Pathol; 2023 Jan; 33(1):e13129. PubMed ID: 36409151 [TBL] [Abstract][Full Text] [Related]
78. Pharmacological Signature and Target Specificity of Inhibitory Circuits Formed by Martinotti Cells in the Mouse Barrel Cortex. Donato C; Balduino Victorino D; Cabezas C; Aguirre A; Lourenço J; Potier MC; Zorrilla de San Martin J; Bacci A J Neurosci; 2023 Jan; 43(1):14-27. PubMed ID: 36384682 [TBL] [Abstract][Full Text] [Related]
79. The Case for Clinical Trials with Novel GABAergic Drugs in Diabetes Mellitus and Obesity. Antoni FA Life (Basel); 2022 Feb; 12(2):. PubMed ID: 35207609 [TBL] [Abstract][Full Text] [Related]
80. Modulation of relapse-like drinking in male Sprague-Dawley rats by ligands targeting the α5GABA Chandler CM; Reeves-Darby J; Jones SA; Li G; Rahman MT; Cook JM; Platt DM Neuropharmacology; 2021 Nov; 199():108785. PubMed ID: 34509495 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]